- Truist has initiated coverage on Verastem Oncology Inc (NASDAQ:VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside.
- Analyst Srikripa Devarakonda notes that trading at about 2-times cash, the stock is "undervalued" given its programs in two cancers.
- Devarakonda adds that the Verastem base case is supported by a $470 million unadjusted U.S. opportunity in the ovarian cancer program, "early but strong" clinical data, and positive expert feedback.
- Related: Verastem Shares Are Trading Higher On Encouraging Combo Therapy Data At ESMO Presentation.
- Verastem's lead program VS-6766 inhibits RAF/MEK signaling pathway.
- The FDA granted Breakthrough Therapy designation for the combination of VS-6766, with defactinib, for recurrent low-grade serous ovarian cancer (LGSOC) regardless of KRAS status after one or more prior lines of therapy.
- The Company is conducting Phase 2 registration-directed trials of VS-6766 alone and with defactinib in patients with recurrent LGSOC and recurrent KRAS G12V-mutant NSCLC.
- Verastem Oncology has collaborated with Amgen Inc (NASDAQ:AMGN) and Mirati Therapeutics Inc (NASDAQ:MRTX) to evaluate Sotorasib and Adagrasib in combination with VS-6766.
- Price Action: VSTM shares are up 22.30% at $1.37 during the market session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks